{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:09Z","timestamp":1787028489366,"version":"build-2736575974"},"reference-count":101,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2\u20133% of the general adult population worldwide. The interleukin (IL)-23\/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new targeted pharmacotherapies. Cutaneous lesions tend to recur in the same body areas, likely because of the reactivation of tissue-resident memory T cells. The spillover of different pro-inflammatory cytokines into systemic circulation can promote the onset of different comorbidities, including psoriatic arthritis. New targeted pharmacotherapies may lead to almost complete skin clearance and significant improvements in the patient\u2019s quality of life. Accumulating evidence supports the notion that early intervention with targeted pharmacotherapies could beneficially affect the clinical course of psoriatic disease at three different levels: (1) influencing the immune cells infiltrating the skin and gene expression, (2) the prevention of psoriasis-related comorbidities, especially psoriatic arthritis, and (3) the improvement of the patient\u2019s quality of life and reduction of cumulative life course impairment. The main aim of this narrative review is to summarize the effects that new targeted pharmacotherapies for psoriasis may have on the immune scar, both at the molecular and cellular level, on psoriatic arthritis and on the patient\u2019s quality of life.<\/jats:p>","DOI":"10.3390\/ijms232112849","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:00:27Z","timestamp":1666735227000},"page":"12849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Could Targeted Pharmacotherapies Exert a \u201cDisease Modification Effect\u201d in Patients with Chronic Plaque Psoriasis?"],"prefix":"10.3390","volume":"23","author":[{"given":"Francesco","family":"Bellinato","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00144 Rome, Italy"},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica Del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-4733","authenticated-orcid":false,"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medicine, University of Padua, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related Genes","volume":"131","author":"Lowes","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"Tomalin","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17\u2013producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jid.2019.09.027","article-title":"Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy","volume":"140","author":"Mashiko","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1346-8138.15822","article-title":"Persistent expression of interleukin-17 and downstream effector cytokines in recalcitrant psoriatic lesions after ustekinumab treatment","volume":"48","author":"Kim","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","article-title":"Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept","volume":"143","author":"Brodmerkel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.jid.2018.02.030","article-title":"Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome","volume":"138","author":"Classon","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.40778","article-title":"Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two\u2013Week, Prospective, Open-Label Feasibility Study","volume":"71","author":"Savage","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","article-title":"Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation\u2014Data from the prospective IVEPSA study","volume":"21","author":"Kampylafka","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Felquer","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.55563\/clinexprheumatol\/8thj0l","article-title":"Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence","volume":"38","author":"Solmaz","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case\u2013Control Study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Karpi\u0144ska-Mirecka, A., Bartosi\u0144ska, J., and Krasowska, D. (2020). The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241604"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s10067-021-06012-y","article-title":"Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results","volume":"41","author":"Ayan","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"Strober","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., and Romanelli, M. (2018). Scanning the Immunopathogenesis of Psoriasis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010179"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14728222.2014.889686","article-title":"Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target?","volume":"18","author":"Chiricozzi","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","article-title":"IL-23\u2013Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A","volume":"186","author":"Rizzo","year":"2011","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0001-7310(14)70014-6","article-title":"Pathogenic role of IL-17 in psoriasis and psoriatic arthritis","volume":"105","author":"Chiricozzi","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nm1605","article-title":"\u03b11\u03b21 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis","volume":"13","author":"Conrad","year":"2007","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.20031482","article-title":"Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-\u03b1","volume":"199","author":"Boyman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaci.2015.10.046","article-title":"Targeting CD8+ T cells prevents psoriasis development","volume":"138","author":"Villanova","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Res, P.C.M., Piskin, G., de Boer, O., Van Der Loos, C.M., Teeling, P., Bos, J.D., and Teunissen, M.B.M. (2010). Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014108"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ni.1613","article-title":"A critical function for transforming growth factor-\u03b2, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses","volume":"9","author":"Volpe","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23\/IL-17 Axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2\u2013dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.smim.2009.01.004","article-title":"Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids","volume":"21","author":"Conrad","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10875-009-9278-8","article-title":"Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin Diseases","volume":"29","author":"McNutt","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jid.2019.08.444","article-title":"IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis","volume":"140","author":"Catapano","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","first-page":"245","article-title":"Tissue-resident memory T cells in the skin","volume":"69","author":"Khalil","year":"2020","journal-title":"Agents Actions"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjd.17748","article-title":"CD 8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-na\u00efve nonlesional sites of psoriasis possibly in correlation with disease duration","volume":"181","author":"Vo","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jdermsci.2022.02.008","article-title":"Epidermal CD8+CD103+ skin resident memory T cells in psoriasis plaques are reduced in number but remain in the basement membrane zone after topical application of corticosteroid and vitamin D3","volume":"105","author":"Kurihara","year":"2022","journal-title":"J. Dermatol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/jid.2012.456","article-title":"CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-\u03b3, IL-13, IL-17, and IL-22","volume":"133","author":"Hijnen","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"279ra239","DOI":"10.1126\/scitranslmed.3010302","article-title":"Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells","volume":"7","author":"Watanabe","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: A historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2217\/imt-2020-0040","article-title":"Guselkumab in the treatment of moderate-to-severe plaque psoriasis","volume":"12","author":"Puig","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis","volume":"156","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study","volume":"139","author":"Gordon","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator\u2013controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: Post hoc analysis through 64 weeks from reSURFACE 1 trial","volume":"35","author":"Warren","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: Rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1038\/s41598-020-65269-6","article-title":"Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice","volume":"10","author":"Chen","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2020.00529","article-title":"CCR4+ Skin-Tropic Phenotype as a Feature of Central Memory CD8+ T Cells in Healthy Subjects and Psoriasis Patients","volume":"11","author":"Casciano","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/art.41652","article-title":"Tissue-Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis","volume":"73","author":"Leijten","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+ CD 8+ T Cells in Psoriatic Arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"723944","DOI":"10.3389\/fmed.2021.723944","article-title":"Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis","volume":"8","author":"Pennington","year":"2021","journal-title":"Front. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: Focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3899\/jrheum.110505","article-title":"Preliminary Evidence That Subclinical Enthesopathy May Predict Psoriatic Arthritis in Patients with Psoriasis","volume":"38","author":"Tinazzi","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/ker078","article-title":"High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: A prospective case-control study","volume":"50","author":"Naredo","year":"2011","journal-title":"Rheumatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e001067","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: Clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/PTT.S323300","article-title":"Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis","volume":"12","author":"Gisondi","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ogdie, A., Harrison, R.W., McLean, R.R., Lin, T.-C., Lebwohl, M., Strober, B.E., Zhuo, J., Patel, V., and Mease, P.J. (2022). Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J. Am. Acad. Dermatol.","DOI":"10.1016\/j.jaad.2022.07.060"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2021-221255","article-title":"Intercepting psoriatic arthritis in patients with psoriasis: Buy one get one free?","volume":"81","author":"McGonagle","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/17512433.2020.1759415","article-title":"A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis","volume":"13","author":"Bellinato","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_70","unstructured":"Gerriets, V., Goyal, A., and Khaddour, K. (2022). Tumor Necrosis Factor Inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: What is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","article-title":"Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology","volume":"149","author":"Salas","year":"1999","journal-title":"Am. J. Epidemiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","article-title":"Cumulative life course impairment in psoriasis: Patient perception of disease-related impairment throughout the life course","volume":"164","author":"Warren","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","article-title":"Psoriasis: Is the impairment to a patient\u2019s life cumulative?","volume":"24","author":"Kimball","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","first-page":"102","article-title":"Psoriasis\u2014The Life Course Approach","volume":"96","author":"Linder","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2133.2002.04899.x","article-title":"Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients","volume":"147","author":"Vardy","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/000155550410021583","article-title":"Significance of the Stigmatization Experience of Psoriasis Patients: A 1-Year Follow-up of the Illness and its Psychosocial Consequences in Men and Women","volume":"85","author":"Sittig","year":"2005","journal-title":"Acta Derm. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2133.2003.05391.x","article-title":"Stigmatization and psoriasis","volume":"149","author":"Richards","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/jdv.15065","article-title":"Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: Results of the Clear About Psoriasis worldwide survey","volume":"32","author":"Armstrong","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bjd.14875","article-title":"Predictors of perceived stigmatization in patients with psoriasis","volume":"176","author":"Ferwerda","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2340\/00015555-1193","article-title":"Patients with Psoriasis Feel Stigmatized","volume":"92","author":"Szepietowski","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-4362.1993.tb05031.x","article-title":"Psychosocial Consequences of Rejection and Stigma Feelings in Psoriasis Patients","volume":"32","author":"Ginsburg","year":"1993","journal-title":"Int. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjd.15292","article-title":"Facing the dilemma of patient-centred psoriasis care: A qualitative study identifying patient needs in dermatological outpatient clinics","volume":"177","author":"Khoury","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000093848","article-title":"Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with Psoriasis","volume":"213","author":"Schmitt","year":"2006","journal-title":"Dermatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000098574","article-title":"Impairment of Sexual Life in Patients with Psoriasis","volume":"214","author":"Sampogna","year":"2007","journal-title":"Dermatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00128071-200304120-00003","article-title":"Psychiatric and Psychological Co-Morbidity in Patients with Dermatologic Disorders","volume":"4","author":"Gupta","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1440-0960.2004.00078.x","article-title":"Psychiatric morbidity in psoriasis: A review","volume":"45","author":"Russo","year":"2004","journal-title":"Australas. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000090652","article-title":"An Italian Study on Psoriasis and Depression","volume":"212","author":"Esposito","year":"2006","journal-title":"Dermatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/jdv.14449","article-title":"The association between the clinical diversity of psoriasis and depressive symptoms: The HUNT Study, Norway","volume":"31","author":"Modalsli","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/jdv.12138","article-title":"Disease characteristics in patients with and without psoriatic arthritis treated with etanercept","volume":"28","author":"Papp","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_92","first-page":"280","article-title":"The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jdv.13891","article-title":"The prevalence of anxiety in patients with psoriasis: A systematic review of observational studies and clinical trials","volume":"31","author":"Fleming","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1365-2133.2011.10345.x","article-title":"Alcohol misuse in patients with psoriasis: Identification and relationship to disease severity and psychological distress","volume":"164","author":"McAleer","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jdv.14204","article-title":"Addiction: An underestimated problem in psoriasis health care","volume":"31","author":"Zink","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaad.2007.07.023","article-title":"Association of patient-reported psoriasis severity with income and employment","volume":"57","author":"Horn","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/09546634.2018.1506077","article-title":"A cross-sectional study in young adults with psoriasis: Potential determining factors in quality of life, life course and work productivity","volume":"30","author":"Bronckers","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Hung, W.-K., Tung, T.-H., Wang, T.-Y., Liao, S.-C., and Chi, C.-C. (2022). Risk for incident suicidality among psoriasis patients: A systematic review and meta-analysis. Arch. Dermatol. Res., 1\u201311.","DOI":"10.1007\/s00403-022-02377-5"},{"key":"ref_99","first-page":"91","article-title":"Efficacy of Biofeedback and Cognitive-behavioural Therapy in Psoriatic PatientsA Single-blind, Randomized and Controlled Study with Added Narrow-band Ultraviolet B Therapy","volume":"96","author":"Piaserico","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"adv00422","DOI":"10.2340\/00015555-3712","article-title":"Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study","volume":"101","author":"Talamonti","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/jdv.12909","article-title":"Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review","volume":"29","author":"Fleming","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:10Z","timestamp":1760144530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":101,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232112849"],"URL":"https:\/\/doi.org\/10.3390\/ijms232112849","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}